全文获取类型
收费全文 | 575篇 |
免费 | 91篇 |
国内免费 | 61篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 23篇 |
妇产科学 | 4篇 |
基础医学 | 72篇 |
口腔科学 | 7篇 |
临床医学 | 103篇 |
内科学 | 119篇 |
皮肤病学 | 10篇 |
神经病学 | 18篇 |
特种医学 | 87篇 |
外科学 | 118篇 |
综合类 | 22篇 |
预防医学 | 14篇 |
眼科学 | 6篇 |
药学 | 52篇 |
中国医学 | 1篇 |
肿瘤学 | 70篇 |
出版年
2021年 | 10篇 |
2019年 | 5篇 |
2018年 | 6篇 |
2017年 | 6篇 |
2015年 | 12篇 |
2014年 | 14篇 |
2013年 | 13篇 |
2012年 | 11篇 |
2011年 | 13篇 |
2010年 | 17篇 |
2009年 | 22篇 |
2008年 | 12篇 |
2007年 | 50篇 |
2006年 | 24篇 |
2005年 | 26篇 |
2004年 | 10篇 |
2003年 | 12篇 |
2002年 | 27篇 |
2001年 | 14篇 |
2000年 | 11篇 |
1999年 | 18篇 |
1998年 | 33篇 |
1997年 | 38篇 |
1996年 | 28篇 |
1995年 | 25篇 |
1994年 | 15篇 |
1993年 | 25篇 |
1992年 | 7篇 |
1991年 | 8篇 |
1990年 | 11篇 |
1989年 | 22篇 |
1988年 | 10篇 |
1987年 | 17篇 |
1986年 | 10篇 |
1985年 | 9篇 |
1984年 | 14篇 |
1983年 | 6篇 |
1981年 | 6篇 |
1980年 | 12篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1976年 | 5篇 |
1975年 | 8篇 |
1973年 | 9篇 |
1972年 | 5篇 |
1971年 | 5篇 |
1969年 | 9篇 |
1968年 | 8篇 |
1967年 | 5篇 |
1966年 | 4篇 |
排序方式: 共有727条查询结果,搜索用时 375 毫秒
91.
92.
The incidence of sarcomas of the gastrointestinal tract has remained the same, but gastrointestinal lymphomas are gradually contributing a larger percentage of malignant gastrointestinal neoplasms. The authors have examined their more recent experience with these relatively rare lesions. Twenty-eight patients (13 with lymphoma, 15 with sarcoma) have been treated at the Vanderbilt University and the Metropolitan Nashville General Hospital since 1976. There were eight men in the group with lymphoma and six in the group with sarcoma. The average age for patients with lymphoma was 66 years; the average age was 57 years in the patients with sarcoma. Seven patients with lymphoma and eight patients with sarcoma had been treated for 6 months to 3 years for presumed peptic ulcer disease. Eight of these 15 patients were found to have perforated tumors at the time of surgical exploration. Three patients (all in the group with sarcoma) had metastatic liver disease or peritoneal implants at the time of diagnosis. Treatment for most patients included resection of the tumor, followed by chemotherapy or radiation in cases of tumor perforation or metastatic disease. The survival rate for patients with lymphoma has averaged 5.5 years, with a 55% 5-year survival rate. Patients with cleaved cell tumors survived longer than those with other types of lymphoma. In the group with sarcoma, the survival rate has been 3.1 years on the average, with a 21% 5-year survival rate. 相似文献
93.
CL Martyn-Simmons L Green G Ash RW Groves CH Smith JNWN Barker 《Journal of the European Academy of Dermatology and Venereology》2009,23(12):1394-1397
Background Targeted biologic therapies have made a significant impact on the treatment for moderate to severe psoriasis. In the United Kingdom, the National Institute for Health and Clinical Excellence recommends etanercept, a human recombinant tumour necrosis factor (TNF) receptor fusion protein, for moderate to severe psoriasis patients who have failed conventional therapies. There is, however, no data available on the role of other TNF antagonists for patients who have failed etanercept. Adalimumab, a fully human, anti-TNF monoclonal antibody, is approved for treatment of moderate to severe psoriasis.
Objectives To assess the efficacy and safety of adalimumab (40 mg weekly) in psoriasis patients who were non-responders to high-dosage etanercept (50 mg twice weekly).
Methods All patients attending a tertiary referral service for severe psoriasis who were non-responders to high-dosage etanercept [i.e. failed to achieve ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50) after 12 weeks of treatment] were considered for open-label adalimumab therapy for 12 weeks. Details on clinical course, PASI, Dermatology Life Quality Index (DLQI) and adverse events were recorded at baseline and weeks 2, 4, 8, and 12.
Results Four of five patients in this study had reached at least PASI 50 by week 12. Of these, two patients achieved a 75% improvement in PASI (PASI 75). No serious adverse events were reported.
Conclusions Initial data from this open-label prospective evaluation suggests that weekly adalimumab therapy is an effective treatment for patients with severe psoriasis who had failed to respond to at least 3 months of high-dosage etanercept. 相似文献
Objectives To assess the efficacy and safety of adalimumab (40 mg weekly) in psoriasis patients who were non-responders to high-dosage etanercept (50 mg twice weekly).
Methods All patients attending a tertiary referral service for severe psoriasis who were non-responders to high-dosage etanercept [i.e. failed to achieve ≥ 50% improvement in Psoriasis Area and Severity Index (PASI 50) after 12 weeks of treatment] were considered for open-label adalimumab therapy for 12 weeks. Details on clinical course, PASI, Dermatology Life Quality Index (DLQI) and adverse events were recorded at baseline and weeks 2, 4, 8, and 12.
Results Four of five patients in this study had reached at least PASI 50 by week 12. Of these, two patients achieved a 75% improvement in PASI (PASI 75). No serious adverse events were reported.
Conclusions Initial data from this open-label prospective evaluation suggests that weekly adalimumab therapy is an effective treatment for patients with severe psoriasis who had failed to respond to at least 3 months of high-dosage etanercept. 相似文献
94.
95.
Guidelines for international collaborative research 总被引:2,自引:1,他引:1
OBJECTIVE: As the global village becomes a reality, there is an increasing
need to conduct international collaborative studies in family practice. A
workshop at the WONCA meeting in Hong Kong used international attendees to
produce a set of guidelines for international research. METHODS: At the
workshop four completed international projects, each using a different
strategy, were presented so that common themes might become apparent. The
themes were then discussed and guidelines emerged from the process.
RESULTS: Seven guidelines emerged for consideration before embarking on an
international collaborative research project in family medicine. The
guidelines deal with the characteristics of the research question and the
importance of communication. The need for simple, brief methods of data
collection, funding and pilot testing were identified. CONCLUSION: The
question must be relevant to all participants to maintain interest and
measurement tools must be validated to understand the impact of cultural
differences in understanding.
相似文献
96.
S Rohatagi J S Barrett W Sawyers K Yu R J Morales 《American journal of therapeutics》1997,4(7-8):229-238
Ipriflavone (IP) is a derivative of naturally occurring isoflavones and is marketed as Osteofix for the treatment of osteoporosis in Europe. IP has poor aqueous solubility, and the Osteofix compressed tablet has poor and variable bioavailability (F ). IP is incompletely absorbed after oral administration and is converted to five major metabolites (M1, M2, M3, M4, and M5). It is also further converted to metabolites M6 and M7 to a very small extent. The metabolites, especially M2 and M5, also have activity. A pilot study was conducted in healthy male volunteers that showed an 8- to 20-fold increase in the IP bioavailability after administration of Osteofix tablets in the fed state relative to the fasting state. A four-way crossover study was conducted in 16 healthy male volunteers, receiving Osteofix in fed state and 50, 100, and 200 mg of IP corn-oil suspension in fasted state. All IP administrations were safe and well tolerated. There was a reduction in the IP plasma level variability after 100-mg corn-oil administration as compared with that for the tablet. There was an increased relative F after the suspension, which was such that the 50-mg IP corn-oil suspension yielded similar levels as the 200-mg tablet. M5 was the major metabolite, consistent with earlier reports. The area under the curve to the last measured time point (AUC ( t ) ) levels were lower for M5, M3, and M2; higher for M1 and M2; and similar for IP after 50-mg corn-oil administration, as compared with the values for the tablet. This result may partially be explained by differences in the half-lives. Absorption/formation of M2 was delayed. The metabolite formation, except for M1 and M5, decreased with increased doses, which was accompanied by the prolonged half-life of IP and nonproportional increase in the IP AUC ( t ). This result may be due to autoinhibition of IP metabolism, because IP is an inhibitor of CYP3A4, and the metabolism of IP may be partly CYP3A4 mediated. Osteofix F may be improved by formulations that increase solubility, such as the corn-oil suspension. Although equivalent IP exposure from the tablet may be achieved at much lower overall doses because of the improved F by the corn-oil suspension, higher doses may require reconfirmation of safety and efficacy, given the differences in metabolic profiles obtained at higher doses. 相似文献
97.
Colorectal metastases to the liver: selective chemoembolization 总被引:6,自引:0,他引:6
98.
99.
100.